IV Factor VIIa-CTP: Phase IIa started

Opko began an open-label, dose-escalation, U.S. Phase IIa trial to evaluate single doses of IV Factor VIIa-CTP in about 24 adult male patients. Later this year, Opko plans to start a Phase IIa trial o...